WuXi Biologics (Cayman) Inc
HKEX:2269
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.26
46.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc
Accounts Receivables
WuXi Biologics (Cayman) Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Accounts Receivables
¥6.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Accounts Receivables
¥8.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Accounts Receivables
¥2.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Accounts Receivables
¥4.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
31%
|
CAGR 10-Years
33%
|
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Accounts Receivables
¥697.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Accounts Receivables
¥853.3m
|
CAGR 3-Years
225%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
Glance View
WuXi Biologics (Cayman) Inc. is a leading global provider of biologics development and manufacturing solutions, operating at the intersection of healthcare innovation and advanced biotechnology. Founded in 2010, the company has rapidly transformed from a local player into a dominant force that serves pharma and biotech firms worldwide. WuXi Biologics offers a comprehensive suite of services, including cell line development, process development, clinical manufacturing, and commercial production of biologics, helping its partners bring life-saving therapies to market with speed and efficiency. With a robust pipeline of collaborations and a commitment to excellence, WuXi is strategically positioned to capitalize on the growing demand for biologics, particularly in the realms of monoclonal antibodies and gene therapies. For investors, WuXi Biologics represents a compelling opportunity in the rapidly evolving biopharmaceutical landscape. The company’s expansive global network, which includes state-of-the-art facilities in China, Europe, and the United States, allows it to meet rising demand while maintaining high-quality standards. WuXi is well-supported by a solid financial foundation, marked by impressive revenue growth and a strong balance sheet. As regulatory frameworks become more favorable and the biopharma industry continues to innovate, WuXi Biologics stands poised to drive sustainable long-term growth, making it an appealing consideration for investors looking to tap into the promising future of medical therapies.
See Also
What is WuXi Biologics (Cayman) Inc's Accounts Receivables?
Accounts Receivables
6.1B
CNY
Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Accounts Receivables amounts to 6.1B CNY.
What is WuXi Biologics (Cayman) Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
47%
Over the last year, the Accounts Receivables growth was 14%. The average annual Accounts Receivables growth rates for WuXi Biologics (Cayman) Inc have been 28% over the past three years , 47% over the past five years .
You don't have any saved screeners yet
